Science Explorer Back to mapMap
Discussion
Company · Tokushima · Japan

Taiho Pharmaceutical (Japan)

In research, Taiho Pharmaceutical (Japan) stands highest in Oncology (#1,204 of 1,474 worldwide), Medicine (#12,301 of 14,558 worldwide) and Health Sciences (#14,127 of 16,688 worldwide), over all time.

taiho.co.jp/english/index.htmlROR OpenAlex
World rank, all time
#29,945
of 34,923
Rank in Japan
#1,316
of 1,923
Research works
1.2k
▼ 36% vs 2018-21
Citations
24k
20.7 per fractional work
Top-10% rate
9.2%
all institutions 10.0%
vs its own fields
0.68×
1.00× is exactly expected
Open access
42%
world 40%
International
11%
world 18%
Taiho Pharmaceutical (Japan)

What is Taiho Pharmaceutical (Japan) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
OncologySubfield #1,204 of 1,474 9.4%145
MedicineField #12,301 of 14,558 7.9%478
Health SciencesDomain #14,127 of 16,688 7.7%492
Biochemistry, Genetics and Molecular BiologyField #4,961 of 5,801 6.6%331
Molecular BiologySubfield #3,245 of 3,729 7.7%210
Life SciencesDomain #10,063 of 11,023 6.4%462
Physical SciencesDomain #17,056 of 17,446 4.9%217

Each strip is that field's whole ranked pool, with the notch where Taiho Pharmaceutical (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Taiho Pharmaceutical (Japan) work in?

In 2022-now, 46% of research at Taiho Pharmaceutical (Japan) is in Health Sciences, 39% in Life Sciences. Its largest fields are Medicine (44%), Biochemistry, Genetics and Molecular Biology (29%), Immunology and Microbiology (4%). It does 2.4× the world's share of Life Sciences.

Health Sciences: 31 fractional works · 46.2% of its workMedicine: 29 fractional works · 43.7% of its workOncology: 9 fractional works · 13.8% of its workPulmonary and Respiratory Medicine: 5 fractional works · 7.8% of its workRheumatology: 2 fractional works · 3.3% of its workHematology: 2 fractional works · 2.3% of its workSurgery: 2 fractional works · 2.2% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.1% of its workPharmacology: 1 fractional works · 1.3% of its workGastroenterology: 1 fractional works · 1.2% of its workUrology: 1 fractional works · 1.1% of its workGenetics: 1 fractional works · 1.1% of its workInfectious Diseases: 1 fractional works · 1.1% of its workEpidemiology: 1 fractional works · 0.9% of its workPathology and Forensic Medicine: 1 fractional works · 0.9% of its workNeurology: 1 fractional works · 0.8% of its workPhysiology: 0 fractional works · 0.7% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.5% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.5% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.5% of its workDermatology: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.7% of its workHealth Professions: 2 fractional works · 2.3% of its workOccupational Therapy: 1 fractional works · 1.1% of its workGeneral Health Professions: 0 fractional works · 0.7% of its workPharmacy: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.2% of its workLife Sciences: 26 fractional works · 38.5% of its workBiochemistry, Genetics and Molecular Biology: 19 fractional works · 28.8% of its workMolecular Biology: 14 fractional works · 21.2% of its workCell Biology: 2 fractional works · 3.4% of its workBiotechnology: 1 fractional works · 1.4% of its workCancer Research: 1 fractional works · 1.1% of its workGenetics: 1 fractional works · 1.0% of its workBiochemistry: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.4% of its workImmunology and Microbiology: 3 fractional works · 4.4% of its workImmunology: 3 fractional works · 4.4% of its workAgricultural and Biological Sciences: 2 fractional works · 2.9% of its workPlant Science: 1 fractional works · 1.5% of its workFood Science: 1 fractional works · 0.9% of its workAquatic Science: 0 fractional works · 0.3% of its workInsect Science: 0 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.6% of its workPharmacology: 1 fractional works · 1.0% of its workPharmaceutical Science: 0 fractional works · 0.4% of its workToxicology: 0 fractional works · 0.3% of its workNeuroscience: 1 fractional works · 0.8% of its workNeurology: 0 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPhysical Sciences: 10 fractional works · 14.5% of its workEngineering: 3 fractional works · 3.9% of its workMechanical Engineering: 1 fractional works · 1.5% of its workBiomedical Engineering: 1 fractional works · 1.2% of its workElectrical and Electronic Engineering: 0 fractional works · 0.5% of its workAerospace Engineering: 0 fractional works · 0.3% of its workSafety, Risk, Reliability and Quality: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workChemistry: 3 fractional works · 3.8% of its workOrganic Chemistry: 2 fractional works · 2.4% of its workInorganic Chemistry: 0 fractional works · 0.7% of its workAnalytical Chemistry: 0 fractional works · 0.4% of its workSpectroscopy: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysics and Astronomy: 2 fractional works · 3.0% of its workAstronomy and Astrophysics: 2 fractional works · 2.5% of its workNuclear and High Energy Physics: 0 fractional works · 0.5% of its workEnvironmental Science: 1 fractional works · 1.7% of its workEcology: 0 fractional works · 0.7% of its workNature and Landscape Conservation: 0 fractional works · 0.5% of its workEnvironmental Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workMaterials Science: 1 fractional works · 1.2% of its workMaterials Chemistry: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.5% of its workComputer Science: 1 fractional works · 0.9% of its workComputational Theory and Mathematics: 0 fractional works · 0.7% of its workComputer Science Applications: 0 fractional works · 0.3% of its workSocial Sciences: 1 fractional works · 0.8% of its workBusiness, Management and Accounting: 0 fractional works · 0.5% of its workManagement of Technology and Innovation: 0 fractional works · 0.3% of its workMarketing: 0 fractional works · 0.3% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.3% of its workEconomics and Econometrics: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.1% of its workALL ITS WORKTaihoPharmaceutical…67fractional works, 2022-now
Life Sciences39%Physical Sciences15%Health Sciences46%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 17 fields, with their numbers
    1. Medicine2943.7%
    2. Health Professions22.3%
    3. Nursing00.2%
    1. Biochemistry, Genetics and Molecular Biology1928.8%
    2. Immunology and Microbiology34.4%
    3. Agricultural and Biological Sciences22.9%
    4. Pharmacology, Toxicology and Pharmaceutics11.6%
    5. Neuroscience10.8%
    1. Engineering33.9%
    2. Chemistry33.8%
    3. Physics and Astronomy23.0%
    4. Environmental Science11.7%
    5. Materials Science11.2%
    6. Computer Science10.9%
    1. Business, Management and Accounting00.5%
    2. Economics, Econometrics and Finance00.3%
    3. Social Sciences00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.60× its world share, 2 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 5.40× its world share, 19 worksBiochemistry, Geneti…Immunology and Microbiology: 4.37× its world share, 3 worksImmunology and Micro…Neuroscience: 0.51× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 4.66× its world share, 1 worksPharmacology, Toxico…Chemistry: 2.41× its world share, 2 worksChemistryComputer Science: 0.11× its world share, 1 worksComputer ScienceEngineering: 0.26× its world share, 3 worksEngineeringEnvironmental Science: 0.35× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.34× its world share, 1 worksMaterials SciencePhysics and Astronomy: 1.34× its world share, 2 worksPhysics and AstronomyHealth Professions: 0.89× its world share, 2 worksHealth ProfessionsMedicine: 2.27× its world share, 29 worksMedicineNursing: 0.34× its world share, 0 worksNursingBusiness, Management and Accounting: 0.15× its world share, 0 worksBusiness, Management…Economics, Econometrics and Finance: 0.12× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.4×. Every wedge is a field page.

All 16 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology5.40×19 works
  2. Pharmacology, Toxicology and Pharmaceutics4.66×1 works
  3. Immunology and Microbiology4.37×3 works
  4. Chemistry2.41×2 works
  5. Medicine2.27×29 works
  6. Physics and Astronomy1.34×2 works
  7. Health Professions0.89×2 works
  8. Agricultural and Biological Sciences0.60×2 works
  9. Neuroscience0.51×1 works
  10. Environmental Science0.35×1 works
  11. Materials Science0.34×1 works
  12. Nursing0.34×0 works
  13. Engineering0.26×3 works
  14. Business, Management and Accounting0.15×0 works
  15. Economics, Econometrics and Finance0.12×0 works
  16. Computer Science0.11×1 works

Who are the top researchers at Taiho Pharmaceutical (Japan)?

Ranked on the quality score, Kazuhiko Yonekura, Naomoto Harada and Kaoru Funabashi lead among researchers whose main affiliation is Taiho Pharmaceutical (Japan).

  1. 1 Kazuhiko Yonekura Japan · #1,137,390 worldwide 1.7k citations · 71 works
  2. 2 Naomoto Harada Japan · #1,156,256 worldwide 2.8k citations · 22 works
  3. 3 Kaoru Funabashi Japan · #1,334,957 worldwide 676 citations · 34 works
  4. 4 Kazutaka Miyadera Japan · #1,755,298 worldwide 2.5k citations · 105 works
  5. 5 Hidenori Fujita Japan · #2,023,548 worldwide 427 citations · 41 works
  6. 6 Hiroshi Sootome Japan · #2,139,290 worldwide 1.4k citations · 59 works
  7. 7 Yoshihisa Nozawa Japan · #2,268,086 worldwide 3.9k citations · 74 works
  8. 8 Satoru Ito Japan · #2,750,902 worldwide 463 citations · 22 works
  9. 9 Yayoi Fujioka Japan · #2,915,162 worldwide 390 citations · 37 works
  10. 10 Hiroaki Ochiiwa Japan · #3,121,905 worldwide 429 citations · 53 works
All ranked researchers at Taiho Pharmaceutical (Japan)

What are the most cited papers from Taiho Pharmaceutical (Japan)?

The most cited paper from Taiho Pharmaceutical (Japan) is "Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer" (Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai et al., 2011), with 1,495 citations. Next come "Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer" (1,457) and "NCCN Guidelines Insights: Colon Cancer, Version 2.2018" (1,045).

Most cited papers
#PaperReleasedCitations
1 Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai et al. · Journal of Clinical Oncology Open access 18 Oct 2011 1,495
2 Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer Robert J. Mayer et al. · New England Journal of Medicine Open access 13 May 2015 1,457
3 NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network Open access Apr 2018 1,045
4 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs Jul 1996 825
5 Modulation of oestrogen receptor signalling by association with the activated dioxin receptor Fumiaki Ohtake, Ken‐ichi Takeyama, Takahiro Μatsumoto et al. · Nature May 2003 797
All 59 most cited papers, with filters and sorting

Which keywords describe research at Taiho Pharmaceutical (Japan)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer, Chemotherapy, Cancer Therapy, Metabolism, Targeted Therapy, Clinical Trials, Signaling and Immunotherapy.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer7▲ 7.5×15 topics
  2. Chemotherapy6▲ 12×8 topics
  3. Cancer Therapy5▲ 13×13 topics
  4. Metabolism5▲ 13×5 topics
  5. Targeted Therapy5▲ 30×5 topics
  6. Clinical Trials4▲ 9.0×4 topics
  7. Signaling4▲ 99×2 topics
  8. Immunotherapy4▲ 7.6×9 topics
  9. Therapy3▲ 24×3 topics
  10. Inflammation3▲ 2.1×17 topics
  11. Development3▲ 12×2 topics
  12. FGF213▲ 346×1 topic
  13. Fibroblast Growth Factor3▲ 346×1 topic
  14. Genomic Profiling3▲ 42×2 topics
  15. Monoclonal Antibody3▲ 75×2 topics
  16. Prognostic Factors3▲ 9.5×6 topics
  17. Treatment Guidelines3▲ 18×2 topics
  18. ALK Inhibitors2▲ 54×1 topic
  19. EGFR Mutations2▲ 54×1 topic
  20. Genetic Mutations2▲ 7.0×6 topics
  21. Monoclonal Antibodies2▲ 33×3 topics
  22. Mutation2▲ 17×3 topics
  23. Tumor Microenvironment2▲ 6.7×5 topics
  24. Breast Cancer2▲ 11×3 topics
  25. Biomarkers2▲ 3.8×3 topics
  26. HER22▲ 82×1 topic
  27. Imatinib Mesylate2▲ 54×2 topics
  28. Trastuzumab2▲ 52×1 topic
  29. Anticancer Agents2▲ 17×5 topics
  30. Glycosylation2▲ 24×3 topics
  31. Biopharmaceuticals2▲ 46×3 topics
  32. Cell Signaling2▲ 15×8 topics
  33. Innate Immunity2▲ 7.4×5 topics
  34. Precision Medicine2▲ 4.7×3 topics
  35. Immunogenicity2▲ 51×2 topics
  36. Cell Proliferation1▲ 23×3 topics
  37. PET Imaging1▲ 12×4 topics
  38. Therapeutic Antibodies1▲ 28×2 topics
  39. Fusion Genes1▲ 79×1 topic
  40. Tumor Markers1▲ 22×2 topics

Which research topics does Taiho Pharmaceutical (Japan) publish most on?

By volume in 2022-now: Fibroblast Growth Factor Research, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research and Colorectal Cancer Treatments and Studies.

Fibroblast Growth Factor Research: 3 fractional worksLung Cancer Treatments and Mutations: 2 fractional worksHER2/EGFR in Cancer Research: 2 fractional worksColorectal Cancer Treatments and Studies: 1 fractional worksEosinophilic Disorders and Syndromes: 1 fractional worksMicrotubule and mitosis dynamics: 1 fractional worksChronic Myeloid Leukemia…1Chronic Myeloid Leukemia Treatments: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksViral Infectious Diseases and Gene Expression in Insects: 1 fractional worksPI3K/AKT/mTOR signaling …1PI3K/AKT/mTOR signaling in cancer: 1 fractional works
Molecular BiologyPulmonary and Respiratory MedicineOncologyRheumatology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Fibroblast Growth Factor Research Molecular Biology 3 works
  2. 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
  3. 3 HER2/EGFR in Cancer Research Oncology 2 works
  4. 4 Colorectal Cancer Treatments and Studies Oncology 1 works
  5. 5 Eosinophilic Disorders and Syndromes Rheumatology 1 works
  6. 6 Microtubule and mitosis dynamics Cell Biology 1 works
  7. 7 Chronic Myeloid Leukemia Treatments Hematology 1 works
  8. 8 Cancer Immunotherapy and Biomarkers Oncology 1 works
  9. 9 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 1 works
  10. 10 PI3K/AKT/mTOR signaling in cancer Molecular Biology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available41.5%not open58.5%

World: 40% of research is openly available.

with international co-authors10.8%domestic only89.2%

World: 18% is written across borders.

How has Taiho Pharmaceutical (Japan)'s research output changed?

Output in 2022-2025 was 36% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Taiho Pharmaceutical (Japan) as a percentage of every work published that year, 0.00019% in 2024.

still counting0.0020%0.0040%0.0060%Taiho Pharmaceutical (Japan)0.00022% in 202519801990200020102020

Fractional works of Taiho Pharmaceutical (Japan) over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year, against all institutions in the same year.

10%20%30%Taiho Pharmaceutical (Japan)12.0% in 2023all institutions10.0% in 2023200020102020

Of each year's output, the share that reached the world's 10% most cited for its field and year. Peak 20.3% in 1993.

Other research institutions in Tokushima

All research institutions in Tokushima

Share Taiho Pharmaceutical (Japan)'s ranking

Taiho Pharmaceutical (Japan) on Science Explorer

A card with Taiho Pharmaceutical (Japan)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Taiho Pharmaceutical (Japan). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.